| 12398119 |
Piperazine azaspiro derivatives |
Lei Zhang, Erik Alphie LaChapelle, Christopher Ryan Butler, Natasha Mariam Kablaoui, Michael Aaron Brodney +3 more |
2025-08-26 |
|
| 12049465 |
Tricyclic compounds and their use as phosphodiesterase inhibitors |
Thomas Allen Chappie, Nandini Chaturbhai Patel, Patrick Robert Verhoest, Simone Sciabola, Erik Alphie LaChapelle +2 more |
2024-07-30 |
$542,147,000 |
| 11524954 |
Piperazine azaspiro derivatives |
Lei Zhang, Erik Alphie LaChapelle, Christopher Ryan Butler, Natasha Mariam Kablaoui, Michael Aaron Brodney +3 more |
2022-12-13 |
$1,137,745,000 |
| 11472805 |
Tricyclic compounds and their use as phosphodiesterase inhibitors |
Thomas Allen Chappie, Nandini Chaturbhai Patel, Patrick Robert Verhoest, Simone Sciabola, Erik Alphie LaChapelle +2 more |
2022-10-18 |
$393,425,000 |
| 11312713 |
Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors |
Michael Aaron Brodney, Thomas Allen Chappie, Jinshan Chen, Jotham Wadsworth Coe, Karen Coffman +14 more |
2022-04-26 |
$777,515,000 |
| 11161844 |
Cyclic substituted imidazo[4,5-c]quinoline derivatives |
Thomas Allen Chappie, Paul Galatsis, Michelle Renee Garnsey, Jaclyn Louise Henderson, Bethany Lyn Kormos +5 more |
2021-11-02 |
$709,757,000 |
| 10858373 |
Heterocyclic spiro compounds as MAGL inhibitors |
Michael Aaron Brodney, Christopher Ryan Butler, Laura Ann McAllister, Steven Victor O'Neil, Patrick Robert Verhoest |
2020-12-08 |
$1,644,744,000 |
| 10738063 |
6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds |
Thomas Allen Chappie, Nandini Chaturbhai Patel, Patrick Robert Verhoest, Simone Sciabola, Erik Alphie LaChapelle +2 more |
2020-08-11 |
$655,725,000 |
| 10723711 |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors |
Christopher Ryan Butler, Laura Ann McAllister, Elizabeth Mary Beck, Michael Aaron Brodney, Adam Matthew Gilbert +6 more |
2020-07-28 |
$482,302,000 |
| 10669279 |
Imidazopyridazine compounds |
Thomas Allen Chappie, Nandini Chaturbhai Patel, Matthew Merrill Hayward, Simone Sciabola, Erik Alphie LaChapelle +2 more |
2020-06-02 |
$395,652,000 |
| 10626125 |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors |
Michael Aaron Brodney, Christopher Ryan Butler, Laura Ann McAllister, Steven Victor O'Neil, Patrick Robert Verhoest |
2020-04-21 |
$1,173,015,000 |
| 10428034 |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors |
Christopher Ryan Butler, Laura Ann McAllister, Elizabeth Mary Beck, Michael Aaron Brodney, Adam Matthew Gilbert +6 more |
2019-10-01 |
$298,967,000 |
| 10329308 |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors |
Michael Aaron Brodney, Christopher Ryan Butler, Laura Ann McAllister, Steven Victor O'Neil, Patrick Robert Verhoest |
2019-06-25 |
$317,230,000 |
| 10323042 |
6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds |
Thomas Allen Chappie, Nandini Chaturbhai Patel, Patrick Robert Verhoest, Simone Sciabola, Erik Alphie LaChapelle +2 more |
2019-06-18 |
$923,940,000 |
| 10131669 |
Pyrazolopyrimidine compounds |
Thomas Allen Chappie, Patrick Robert Verhoest, Nandini Chaturbhai Patel, Matthew Merrill Hayward, Simone Sciabola +3 more |
2018-11-20 |
$851,493,000 |
| 10077269 |
Imidazopyridazine compounds |
Thomas Allen Chappie, Nandini Chaturbhai Patel, Matthew Merrill Hayward, Simone Sciabola, Erik Alphie LaChapelle +2 more |
2018-09-18 |
$396,134,000 |
| 9845301 |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors |
Christopher Ryan Butler, Laura Ann McAllister, Elizabeth Mary Beck, Michael Aaron Brodney, Adam Matthew Gilbert +6 more |
2017-12-19 |
$261,240,000 |
| 9598421 |
Imidazopyridazine compounds |
Thomas Allen Chappie, Patrick Robert Verhoest, Nandini Chaturbhai Patel, Matthew Merrill Hayward, Simone Sciabola +2 more |
2017-03-21 |
$801,098,000 |
| 9550795 |
Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
Michael Aaron Brodney, Christopher Ryan Butler, Brian Thomas O'Neill |
2017-01-24 |
$366,815,000 |
| 9296761 |
Triazine derivatives |
Thomas Allen Chappie, Bethany Lyn Kormos, Jamison Bryce Tuttle, Patrick Robert Verhoest |
2016-03-29 |
$310,571,000 |
| 9200000 |
Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders |
Thomas Allen Chappie, John Michael Humphrey, Patrick Robert Verhoest, Eddie Yang |
2015-12-01 |
$346,715,000 |
| 9145427 |
Triazine derivatives |
Thomas Allen Chappie, Bethany Lyn Kormos, Jamison B. Tuttle, Patrick Robert Verhoest |
2015-09-29 |
$193,164,000 |
| 8933221 |
Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
Michael Aaron Brodney, Christopher Ryan Butler, Brian Thomas O'Neill |
2015-01-13 |
$137,387,000 |
| 8933224 |
Triazine derivatives |
Thomas Allen Chappie, Bethany Lyn Kormos, Jamison Bryce Tuttle, Patrick Robert Verhoest |
2015-01-13 |
$137,387,000 |
| 8829010 |
Pyrazolo[3,4-d]pyrimidine compounds and their use as PDE2 inhibitors and/or CYP3A4 inhibitors |
Thomas Allen Chappie, John Michael Humphrey |
2014-09-09 |
$296,433,000 |
